Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function
fnarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fnarena.com Daily Mail and Mail on Sunday newspapers.
ATH434 protects brain cells and improves motor function in Parkinsonian disorder
Oral presentation at the American Academy of Neurology
News provided by
Share this article
MELBOURNE, Australia
, April 21, 2021 /PRNewswire/ Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ( Alterity or the Company ) today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at the American Academy of Neurology (AAN) virtual annual meeting.
The AAN conference, held this week, is the world s preeminent clinical and scientific conference in the neurology space. The presentation titled
ATH434 Preserves Dopaminergic Neurons, Reduces α-synuclein Oligomerization, and Improves Motor Function in a Transgenic Murine Multiple System Atrophy Model